MDMA, politics and medical research: Have we thrown the baby out with the bathwater?

Journal of Psychopharmacology

Volumn 21, Issue 8, 2007, Pages 787-791

  Sessa, Ben ^a   Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; TRYPTOPHAN;

AMINO ACID METABOLISM; ANXIETY DISORDER; DEPRESSION; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HUMAN; MEDICAL RESEARCH; POLITICS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; TRYPTOPHAN DEPLETION;

AFFECT; BIOMEDICAL RESEARCH; DEPRESSION; HUMANS; LEGISLATION, DRUG; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POLITICS; SEROTONIN;

EID: 35648999095     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107084738     Document Type: Editorial

References (31)

1. Bell C.J., Hood S.D., Nutt D.J. (2005) Acute tryptophan depletion. Part II: clinical effects and implications. ANZ J Psychiatry 39 (7). 565 - 574
2. Bonnie, Whitebread C H (1999) The Marijuana Conviction: A History of Marijuana Prohibition in the United States. New York: Drug Policy Alliance. July 1999, 368 - 370
3. Cami J., Farre M., Mas M., Roset P.N., Poudevida S., Mas A., San L., de la Torre R. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ('ecstasy'). psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455 - 466
4. Greer G.R., Tolbert R. (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18 (4). 319 - 327
5. Grinspoon L., Bakalar J.B. (1995) Marihuana as medicine: a plea for reconsideration. JAMA 273 (23). 1875 - 1876
6. Grob C. (2002) Appendix B., Deconstructing Ecstasy: The Politics of MDMA research. From 'Hallucinogens - A Reader'. Published by Tarcher / Putnam.
7. Halpern J.H., Pope H.G., Sherwood A.R., Barry S., Hudson J.I., Yurgelun-Todd D. (2004) Residual neuropsychological effects of illicit MDMA in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135 - 147
8. Hood S.D., Bell C.J., Nutt D.J. (2005) Acute tryptophan depletion. Part I: rationale and methodology. ANZ J Psychiatry 39 (7). 558 - 564
9. Huizink A.C., Ferdinand R.F., van der Ende J., Verhulst F.C. (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. BMJ 332: 825 - 828
10. Iverson L. (2006) Speed, ecstasy, ritalin: the science of amphetamines. Chapter 8, Ecstasy. Pages 151 - 152. Oxford University Press, Oxford
11. Johnson M.P., Hoffma A.J., Nichols D.E. (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269 - 296
12. Lee M.A., Shalin B. (1992) Acid dreams. The complete social history of LSD: the CIA, the sixties and beyond. Chapter 3, Pages 87 - 95. Grove Press, New York
13. Lieb R., Schuetz C., Pfister H., von Sydow K., Wittchen H. (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68 (2). 195
14. Liechti M.E. (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154: 161 - 168
15. Liester M.B., Grob C.S., Bravo G.L., Walsh R.N. (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nervous Mental Dis 180: 345 - 352
16. Ludewig S., Ludewig K., Hasler F., Vollenweides F.X. (2003) No lasting effects of moderate doses of MDMA on memory performance and mood states in healthy humans. Biol Psychiatry 53 (Suppl). 2055
17. Molliver M.E., Berger U.V., Mamounas L.A., Molliver D.C., O'Hearn E., Wislon M.A. (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 640 - 664
18. National Criminal Intelligence Service (2001) UK Threat Assessment 2001, produced by the National Criminal Intelligence Service
19. Nutt D.J., King L.A., Saulsbury W., Blakemore C. (2007) The development of a rational scale to assess the harm of drugs of potential misuse. The Lancet 369: 1047 - 1053
20. Office of National Statistics (2002) - Deaths related to drug poisoning in England and Wales 1993-2000 and 1998-2002. Health Statistic Quarterly, Spring 2003 and Spring 2004
21. Office of National Statistics (2002 and 2003) Mortality Statistics - Review of the Register General on Death in England and Wales, 2002 and 2003
22. Parrott A.C. (2007) The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine). an evidence-based review. Psychopharmacology 191: 181 - 193
23. Reneman L., Endert E., de Bruin K., Lavalaye J., Feenstra M.G., de Wolff F.A., Booij J.L. (2002) The acute and chronic effects of MDMA ('Ecstasy') on cortical 5-HT2A receptors in rat and human brain Neuropsychopharmacology 26: 387396.10.1038/S0893-133X(01)00366-9
24. Ricaurte G., Bryan G., Strauss L., Seiden L., Schuster C. (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986 - 988
25. Riedlinger J., Montagne M. (2001) Potential clinical uses for MDMA. In Holland J (Ed.). Ecstasy: the complete guide: a comprehensive review of the risks and benefits of MDMA. Inner Traditions 261-272
26. Sessa B. (2007) Is there a case for MDMA-assisted psychotherapy in the UK? J Psychopharmacol 21: 220 - 221
27. Shulgin A.T. (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18: 291 - 304
28. Steele D.M., Nichols D.E., Yim G K W (1987) Sterochemical effects of 3,4-methylenedioxymethlyamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes for different regions of rat brain. Biochem Pharmacol 36: 2297 - 2303
29. Sumnall H.R., Cole J.C., Jerome L. (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 2006, Published: On-line
30. UK Home Office (1971) Misuse of drugs act. www.drugs.gov.uk
31. Vollenweider F.X., Gamma A., Liechti M., Huber T. (1998 a) Psychological and cardiovascular effects and short-term sequlae of MDMA ('ecstasy') in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19: 241 - 251